FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB1 day ago · The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of what is already one of the industry’s best-selling medicines. Dupixent is now cleared for use as ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB21 hours ago · In July 2024, Regeneron and Sanofi announced the European Commission approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. Submissions are currently under review with other regulatory authorities around the world, including in Japan.
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB18 hours ago · The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market. The asset is ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB21 hours ago · The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the companies said ...
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
WEB21 hours ago · The FDA has expanded the label of Regeneron and Sanofi's Dupixent to treat COPD. Dupixent becomes the first biologic for COPD patients in the U.S.
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEB21 hours ago · There are 300,000 such people in the U.S., according to Regeneron and Sanofi, which jointly developed Dupixent.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBSep 11, 2024 · Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease. If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union .
Press Release: Dupixent approved in the US as the first-ever ... - Sanofi
WEBSep 27, 2013 · In July 2024, Sanofi and Regeneron announced that the European Medicines Agency approved Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 ... - Sanofi
WEBMay 20, 2024 · Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Dupixent® - Pivotal Trial Results | Sanofi
WEBMar 23, 2006 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through the investigation of two potentially first-in-class biologics, Dupixent and itepekimab.